Various factors can trigger asthma exacerbations, such as viral infections, physical activity, exposure to irritants, allergen exposure in sensitized individuals, and consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) [7]
Mounjaro is more effective and with less side effects than Ozempic/Wegovy, but also can result in increased muscle mass loss due to this efficacy
However, as with any injectable therapy, certain risks and considerations must be understood and appropriately managed
GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range
The authors highlight BPC-157, writing its clinical validation in human subjects is virtually non-existent, and GHK-Cu, stating that injecting it could expose joint tissues to excess copper, impairing cell function
